or Try an Advanced Search...

    Technical Analysis for RPRX - Royalty Pharma plc

    Grade Last Price % Change Price Change
    F 26.19 -0.68% -0.18
    RPRX closed down 0.68 percent on Monday, July 1, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical RPRX trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    MACD Bearish Signal Line Cross Bearish -0.68%
    Outside Day Range Expansion -0.68%
    Lower Bollinger Band Touch Weakness -0.68%
    20 DMA Resistance Bearish -1.47%
    Fell Below 20 DMA Bearish -2.64%
    NR7 Range Contraction -2.64%
    NR7-2 Range Contraction -2.64%
    Older End-of-Day Signals for RPRX ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 6 hours ago
    Fell Below Lower Bollinger Band about 8 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    Rose Above 10 DMA about 10 hours ago
    10 DMA Resistance about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    RPRX Chart by TradingView
    Basic chart:

    Profile

    Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products

    Is RPRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 22 Royalty Pharma plc (NASDAQ:RPRX) is largely controlled by institutional shareholders who own 70% of the company
    Jun 4 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    Jun 3 Royalty Pharma announces pricing of $1.5B of senior unsecured notes
    May 28 Agios in pact with Royalty Pharma for brain tumor candidate
    May 28 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
    May 22 Cytokinetics to get up to $575M in funding from Royalty Pharma
    May 22 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
    May 22 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
    May 13 Royalty Pharma to Present at Upcoming Investor Conferences
    May 12 Here's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter Results
    See more RPRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 31.4194
    52 Week Low 25.3535
    Average Volume 2,818,236
    200-Day Moving Average 27.81
    50-Day Moving Average 27.31
    20-Day Moving Average 26.89
    10-Day Moving Average 26.62
    Average True Range 0.56
    RSI (14) 37.89
    ADX 15.85
    +DI 14.41
    -DI 23.01
    Chandelier Exit (Long, 3 ATRs) 26.03
    Chandelier Exit (Short, 3 ATRs) 27.77
    Upper Bollinger Bands 27.61
    Lower Bollinger Band 26.17
    Percent B (%b) 0.02
    BandWidth 5.38
    MACD Line -0.25
    MACD Signal Line -0.22
    MACD Histogram -0.0327
    Fundamentals Value
    Market Cap 11.7 Billion
    Num Shares 447 Million
    EPS 0.39
    Price-to-Earnings (P/E) Ratio 67.15
    Price-to-Sales 7.40
    Price-to-Book 2.13
    PEG Ratio 0.09
    Dividend 0.79
    Dividend Yield 3.02%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 27.13
    Resistance 3 (R3) 27.21 26.98 26.97
    Resistance 2 (R2) 26.98 26.74 26.94 26.92
    Resistance 1 (R1) 26.59 26.60 26.47 26.50 26.87
    Pivot Point 26.36 26.36 26.30 26.32 26.36
    Support 1 (S1) 25.96 26.12 25.85 25.88 25.51
    Support 2 (S2) 25.73 25.97 25.69 25.46
    Support 3 (S3) 25.34 25.73 25.41
    Support 4 (S4) 25.25